Vir Biotechnology Inc expected to post a loss of 90 cents a share - Earnings Preview

Vir Biotechnology

30/07/2024 21:54

* Vir Biotechnology Inc  VIR.OQ   VIR.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 1
for the period ending January 1 0001
    * The San Francisco California-based  company is expected to
report a 97.4% increase in revenue to $7.497 million from $3.8
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Vir Biotechnology Inc is
for a
loss of 90 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vir
Biotechnology
Inc is $20.00​, above​ its last closing price of $10.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -1.06       -1.05      -0.48     Beat    54.3
 Dec. 31 0001  -1.11       -1.01      -0.86     Beat    14.7
 Sep. 30 2023  -1.25       -1.21      -1.22     Missed  -1.2​
 Jun. 30 2023  -1.19       -1.20      -1.45     Missed  -20.5
 ​​Mar.        -0.74       -0.87      -1.06     Missed  -21.2
 31 2023                                                
 Dec. 31 2022  -0.25       -0.39      -0.76     Missed  -92.4​
 Jan. 1 0001   -0.21       -0.21      1.30      Beat    710.3
 Jun. 30 2022  0.16        0.10       -0.58     Missed  -653.7
 This summary was machine generated July 30 at 20:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)